EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer
“This is an important milestone for EpimAb as we continue on our trajectory to advance our bispecific pipeline and look to explore the potential of our assets for combination therapy,” said Dr.
“Non-small cell lung cancer is one of the most common oncology indications worldwide, yet there remains a huge unmet need among NSCLC patients with EGFR mutations who develop resistance to third-generation TKIs,” said
The planned Phase Ib/II trial will evaluate the safety and tolerability of EMB-01 in combination with Tagrisso® in patients with NSCLC with EGFR mutations. Pharmacokinetics, immunogenicity, and the anti-tumor activity of EMB-01 combined with Tagrisso® will also be assessed.
About EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the
About
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multispecific antibodies, with research and CMC facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006225/en/
EpimAb Biotherapeutics
In the
Dr.
Direct: +1 978-870-6276
Stephan.lensky@epimab.com
In
Dr.
Direct: +86-21-61951011
IR@epimab.com
Dr.
Direct: +86-21-61951014
yesheng.tang@epimab.com
Media Inquiries
MacDougall
+1 781-235-3060
epimab@macdougall.bio
Source: